FDA approves Rhythm Pharmaceuticals' IMCIVREE for acquired hypothalamic obesity in patients aged 4 and older
Reuters
Mar 20
FDA approves Rhythm Pharmaceuticals' IMCIVREE for acquired hypothalamic obesity in patients aged 4 and older
The FDA approved Imcivree (setmelanotide) for acquired hypothalamic obesity.
The label covers adults and pediatric patients aged 4 years and older, for long-term reduction and maintenance of excess body weight.
Approval was supported by the Phase 3 TRANSCEND trial (N=142), which reported an -18.4% placebo-adjusted BMI reduction.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603191830PRIMZONEFULLFEED9675670) on March 19, 2026, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.